On Nov 12, 2025, ANVS reported earnings of -0.37 USD per share (EPS) for Q3 25, missing the estimate of -0.31 USD, resulting in a -18.93% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +15.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.35 USD, with revenue projected to reach -- USD, implying an decrease of -5.41% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Annovis Bio, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Annovis Bio, Inc. reported EPS of -$0.37, missing estimates by -18.93%, and revenue of $0.00, 0% as expectations.
How did the market react to Annovis Bio, Inc.'s Q3 2025 earnings?
The stock price moved up 15.17%, changed from $2.11 before the earnings release to $2.43 the day after.
When is Annovis Bio, Inc. expected to report next?
The next earning report is scheduled for Mar 19, 2026.
What are the forecasts for Annovis Bio, Inc.'s next earnings report?
Based on 5
analysts, Annovis Bio, Inc. is expected to report EPS of -$0.35 and revenue of -- for Q4 2025.